Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Brigatinib is approved by both the FDA and EMA for the treatment of Non-Small-Cell Lung Carcinoma (NSCLC) (ALK m)
No statistically significant differences were identified between brigatinib and alectinib in reducing the risk of disease progression overall, including in patients with baseline central nervous system metastases. Both drugs appeared similar in reducing the risk of disease progression for patients with TKI-naive Non-Small-Cell Lung Carcinoma (NSCLC) (ALK m)
Brigatinib was initially used to treat patients resistant to [Crizotinib](brain://mJL3GDdAqkaf5VXZ3qLM9A/CrizotinibN…